To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Exclusion Criteria

• •Part 1
• •History of hypersensitivity or allergy to any of the study drugs or to drugs of similar chemical classes.
• •A history of clinically significant ECG abnormalities.
• •Known history or current clinically significant arrhythmias.
• •History of hypertension, adrenal or endocrine disease.
• •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
• •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
• •Smokers (use of tobacco products in the previous 3 months).
• •History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
• •A positive Hepatitis B surface antigen or Hepatitis C test result.
• •Part 2
• •Pregnant or nursing (lactating) women.
• •Women of child-bearing potential.
• •Known history or evidence of a secondary form of hypertension
• •Type 1 or type 2 diabetes mellitus.
• •History of heart diseases
• •A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
• •History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.